These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 34253930)

  • 61. Acute Esophageal Necrosis in a Patient With COVID-19.
    Deliwala SS; Gurvits GE
    Am J Gastroenterol; 2021 Oct; 116(10):1977. PubMed ID: 33661144
    [No Abstract]   [Full Text] [Related]  

  • 62. Immunocompromised Patients With COVID-19 Receive Interferon Gamma.
    Abbasi J
    JAMA; 2021 Dec; 326(22):2250. PubMed ID: 34905045
    [No Abstract]   [Full Text] [Related]  

  • 63. COVID-19 in CVID: a Case Series of 17 Patients.
    Greenmyer JR; Joshi AY
    J Clin Immunol; 2022 Jan; 42(1):29-31. PubMed ID: 34669142
    [No Abstract]   [Full Text] [Related]  

  • 64. SARS-CoV-2 viral dynamics in immunocompromised patients.
    Caillard S; Benotmane I; Gautier Vargas G; Perrin P; Fafi-Kremer S
    Am J Transplant; 2021 Apr; 21(4):1667-1669. PubMed ID: 33048424
    [No Abstract]   [Full Text] [Related]  

  • 65. Monitoring and managing SARS-CoV-2 evolution in immunocompromised populations.
    Li P; de Vries AC; Kamar N; Peppelenbosch MP; Pan Q
    Lancet Microbe; 2022 May; 3(5):e325-e326. PubMed ID: 35309711
    [No Abstract]   [Full Text] [Related]  

  • 66. Vascular skin symptoms in COVID-19: a French observational study.
    Bouaziz JD; Duong TA; Jachiet M; Velter C; Lestang P; Cassius C; Arsouze A; Domergue Than Trong E; Bagot M; Begon E; Sulimovic L; Rybojad M
    J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):e451-e452. PubMed ID: 32339344
    [No Abstract]   [Full Text] [Related]  

  • 67. Expecting the unexpected with COVID-19 vaccines.
    Bar-Zeev N; Kochhar S
    Lancet Infect Dis; 2021 Feb; 21(2):150-151. PubMed ID: 33217363
    [No Abstract]   [Full Text] [Related]  

  • 68. Predicting COVID-19 infection risk in people who are immunocompromised by antibody testing.
    Wijaya R; Johnson M; Campbell N; Stuart B; Kelly A; Tipler N; Menne T; Ahearne MJ; Willimott V; Al-Naeeb AB; Fox CP; Collins GP; O'Callaghan A; Davies AJ; Goldblatt D; Lim SH;
    Lancet; 2023 Jul; 402(10396):99-102. PubMed ID: 37393922
    [No Abstract]   [Full Text] [Related]  

  • 69. Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses.
    Benotmane I; Gautier G; Perrin P; Olagne J; Cognard N; Fafi-Kremer S; Caillard S
    JAMA; 2021 Jul; 326(11):1063-5. PubMed ID: 34297036
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Administration of COVID-19 vaccines in immunocompromised patients.
    Negahdaripour M; Shafiekhani M; Moezzi SMI; Amiri S; Rasekh S; Bagheri A; Mosaddeghi P; Vazin A
    Int Immunopharmacol; 2021 Oct; 99():108021. PubMed ID: 34352567
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Autoantibodies neutralizing type I IFNs are present in
    Bastard P; Gervais A; Le Voyer T; Rosain J; Philippot Q; Manry J; Michailidis E; Hoffmann HH; Eto S; Garcia-Prat M; Bizien L; Parra-Martínez A; Yang R; Haljasmägi L; Migaud M; Särekannu K; Maslovskaja J; de Prost N; Tandjaoui-Lambiotte Y; Luyt CE; Amador-Borrero B; Gaudet A; Poissy J; Morel P; Richard P; Cognasse F; Troya J; Trouillet-Assant S; Belot A; Saker K; Garçon P; Rivière JG; Lagier JC; Gentile S; Rosen LB; Shaw E; Morio T; Tanaka J; Dalmau D; Tharaux PL; Sene D; Stepanian A; Megarbane B; Triantafyllia V; Fekkar A; Heath JR; Franco JL; Anaya JM; Solé-Violán J; Imberti L; Biondi A; Bonfanti P; Castagnoli R; Delmonte OM; Zhang Y; Snow AL; Holland SM; Biggs C; Moncada-Vélez M; Arias AA; Lorenzo L; Boucherit S; Coulibaly B; Anglicheau D; Planas AM; Haerynck F; Duvlis S; Nussbaum RL; Ozcelik T; Keles S; Bousfiha AA; El Bakkouri J; Ramirez-Santana C; Paul S; Pan-Hammarström Q; Hammarström L; Dupont A; Kurolap A; Metz CN; Aiuti A; Casari G; Lampasona V; Ciceri F; Barreiros LA; Dominguez-Garrido E; Vidigal M; Zatz M; van de Beek D; Sahanic S; Tancevski I; Stepanovskyy Y; Boyarchuk O; Nukui Y; Tsumura M; Vidaur L; Tangye SG; Burrel S; Duffy D; Quintana-Murci L; Klocperk A; Kann NY; Shcherbina A; Lau YL; Leung D; Coulongeat M; Marlet J; Koning R; Reyes LF; Chauvineau-Grenier A; Venet F; Monneret G; Nussenzweig MC; Arrestier R; Boudhabhay I; Baris-Feldman H; Hagin D; Wauters J; Meyts I; Dyer AH; Kennelly SP; Bourke NM; Halwani R; Sharif-Askari NS; Dorgham K; Sallette J; Sedkaoui SM; AlKhater S; Rigo-Bonnin R; Morandeira F; Roussel L; Vinh DC; Ostrowski SR; Condino-Neto A; Prando C; Bonradenko A; Spaan AN; Gilardin L; Fellay J; Lyonnet S; Bilguvar K; Lifton RP; Mane S; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; Anderson MS; Boisson B; Béziat V; Zhang SY; Vandreakos E; Hermine O; Pujol A; Peterson P; Mogensen TH; Rowen L; Mond J; Debette S; de Lamballerie X; Duval X; Mentré F; Zins M; Soler-Palacin P; Colobran R; Gorochov G; Solanich X; Susen S; Martinez-Picado J; Raoult D; Vasse M; Gregersen PK; Piemonti L; Rodríguez-Gallego C; Notarangelo LD; Su HC; Kisand K; Okada S; Puel A; Jouanguy E; Rice CM; Tiberghien P; Zhang Q; Cobat A; Abel L; Casanova JL
    Sci Immunol; 2021 Aug; 6(62):. PubMed ID: 34413139
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection.
    Yatim N; Boussier J; Tetu P; Smith N; Bruel T; Charbit B; Barnabei L; Corneau A; Da Meda L; Allayous C; Baroudjian B; Jebali M; Herms F; Grzelak L; Staropoli I; Calmettes V; Hadjadj J; Peyrony O; Cassius C; LeGoff J; Kramkimel N; Aractingi S; Fontes M; Blanc C; Rieux-Laucat F; Schwartz O; Terrier B; Duffy D; Lebbé C
    Sci Adv; 2021 Aug; 7(34):. PubMed ID: 34407944
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment.
    Ghandili S; Schönlein M; Lütgehetmann M; Schulze Zur Wiesch J; Becher H; Bokemeyer C; Sinn M; Weisel KC; Leypoldt LB
    Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359701
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients.
    Heudel P; Favier B; Assaad S; Zrounba P; Blay JY
    Ann Oncol; 2021 Nov; 32(11):1443-1444. PubMed ID: 34333128
    [No Abstract]   [Full Text] [Related]  

  • 75. Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
    Benjamini O; Rokach L; Itchaki G; Braester A; Shvidel L; Goldschmidt N; Shapira S; Dally N; Avigdor A; Rahav G; Lustig Y; Ben David SS; Fineman R; Paz A; Bairey O; Polliack A; Levy I; Tadmor T
    Haematologica; 2022 Mar; 107(3):625-634. PubMed ID: 34320789
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination.
    Barros-Martins J; Hammerschmidt SI; Cossmann A; Odak I; Stankov MV; Morillas Ramos G; Dopfer-Jablonka A; Heidemann A; Ritter C; Friedrichsen M; Schultze-Florey C; Ravens I; Willenzon S; Bubke A; Ristenpart J; Janssen A; Ssebyatika G; Bernhardt G; Münch J; Hoffmann M; Pöhlmann S; Krey T; Bošnjak B; Förster R; Behrens GMN
    Nat Med; 2021 Sep; 27(9):1525-1529. PubMed ID: 34262158
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept.
    Chavarot N; Morel A; Leruez-Ville M; Vilain E; Divard G; Burger C; Serris A; Sberro-Soussan R; Martinez F; Amrouche L; Bererhi L; Lanternier F; Legendre C; Zuber J; Anglicheau D; Scemla A
    Am J Transplant; 2021 Dec; 21(12):4043-4051. PubMed ID: 34431207
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant.
    Atanackovic D; Luetkens T; Avila SV; Hardy NM; Lutfi F; Sanchez-Petitto G; Vander Mause E; Glynn N; Mannuel HD; Alkhaldi H; Hankey K; Baddley J; Dahiya S; Rapoport AP
    Vaccines (Basel); 2021 Jul; 9(7):. PubMed ID: 34358153
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
    Benda M; Mutschlechner B; Ulmer H; Grabher C; Severgnini L; Volgger A; Reimann P; Lang T; Atzl M; Huynh M; Gasser K; Petrausch U; Fraunberger P; Hartmann B; Winder T
    Br J Haematol; 2021 Nov; 195(4):523-531. PubMed ID: 34346068
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Scleroderma renal crisis following mRNA vaccination against SARS-CoV-2.
    Oniszczuk J; Pagot E; Limal N; Hüe S; Audard V; Moktefi A; El Karoui K
    Kidney Int; 2021 Oct; 100(4):940-941. PubMed ID: 34339745
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.